← Back

Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Price · split & dividend adjusted
News & notes moving ARVN
Biotech & Genomic Medicine▲

Arvinas maintains cash runway guidance into second half of 2028

Arvinas reported second-quarter 2026 financial results and provided pipeline updates, including a delay in the start of clinical trials for its ARV-102 LRRK2 degrader in progressive supranuclear palsy to 2027. Total revenue for the quarter was $249.7 million, and the company ended the period with $567.9 million in cash, cash equivalents, and marketable securities. CFO Andrew Saik stated that the company continues to maintain its cash runway guidance into the second half of 2028. The revenue included $62.5 million in license revenue and a $50 million milestone from Pfizer, while a Rigel-related accounting change resulted in net revenue of $126.4 million and a liability of $52.7 million for remaining development obligations. CEO Randy Teel highlighted the first FDA approval of a PROTAC degrader, VEPPANU, and its out-licensing to Rigel Pharmaceuticals, as well as the strategic decision to seek a partner for the KRAS G12D program ARV-806. The company expects initial Phase I data for ARV-393 by year-end and plans to share ARV-027 Phase I data in the first half of next year.
ARVN ▲RIGL ▲PFE ▲
Biotech & Genomic Medicine ▼
Seeking Alpha·22dRead more ▾
ARVN

Arvinas Q2 2026 earnings preview shows consensus EPS of -$0.28 and revenue of $60.69M

Arvinas is scheduled to announce its second-quarter 2026 earnings results on Tuesday, August 4th, before market open. The consensus earnings per share estimate is -$0.28, and the consensus revenue estimate is $60.69 million, representing a 170.9% increase year-over-year. Over the last three months, EPS estimates have seen seven upward revisions and three downward revisions, while revenue estimates have seen eight upward revisions and four downward revisions.
ARVN
Seeking Alpha·23dRead more ▾
© 2026 MarketDXAsset